Effectiveness of Trastuzumab Deruxtecan Across HER2-positive Solid Tumors in Patients Without Alternative Treatments: A Hybrid Observational Study

What this Trial Is About

Researchers are evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This observational study is conducted in the US, focusing on real-world settings with patients who have not been treated for breast, colorectal, non-small cell lung, gastric/gastroesophageal junction cancers, or hematological malignancies. The study aims to better understand treatment outcomes in routine clinical care. Participants receive trastuzumab deruxtecan monotherapy as part of their regular treatment based on the FDA label. The study involves about 100 patients enrolled at around 30 sites, including community oncology practices, hospitals, and academic centers. Patients are observed from the start of T-DXd treatment as determined by their clinician, without any experimental intervention assigned by the study. During the study, researchers collect data on tumor response and treatment duration, as well as the time to treatment discontinuation and the time to next treatment. Assessments are carried out through routine clinical evaluations, with follow-up lasting up to 2.5 years after enrollment. This approach helps capture real-world effectiveness and treatment patterns without additional procedures beyond usual care.

DESTINY-PANTUMOUR04